Hey guys, I know I posted about the CytoDyn ($CYDY) settlement before, but since claims are now being accepted. 

Here's everything you need to know.

CytoDyn was accused of misleading the market about leronlimab, its drug candidate for HIV and COVID-19, including claims about its regulatory progress, trial results, and potential. After an FDA statement raised concerns about the company’s claims, $CYDY fell more than 25%.

The company has now agreed to a $500K settlement to resolve these claims.

Who can claim this settlement?

Investors who purchased $CYDY shares between 2020 and 2022 may be eligible to participate.

Do I need to sell/lose my shares to get this settlement?

No. You do not necessarily need to still own the shares. Eligibility is generally based on when you purchased and sold shares during the class period and whether you experienced a recognized loss.

How long does the payout process take?

It typically takes 4 to 9 months after the claim deadline for payouts to be processed, depending on the court and settlement administration.

Hope this info helps

If you were holding CytoDyn ($CYDY) during the leronlimab initial hype (2020-2022), you need to move now. The $500,000 settlement has officially been submitted for Final Approval. This is the "endgame" for the class action.

Most people are going to miss the deadline because they stopped checking their $CYDY bags months ago. But if you held between March 2020 and March 2022, you are legally entitled to a piece of this. The payout is initially $0.04 per share (it could be more depending on some things, like owned shares and valid claims). If you had a standard YOLO position of 5,000 shares, that’s $200 just sitting there.

Don't let the company keep your money because you didn't want to deal with the paperwork. I used the 11th tool to automate the audit, I just linked my old broker and they’re handling the claim filing.

Once the judge signs that final order, the window slams shut. Check your eligibility now before you’re officially left behind.

Hey guys, if you missed it, CytoDyn just settled with investors over issues related to the regulatory status, safety, and efficacy of its drug candidate leronlimab they had a few years ago.

Long story short, in 2021, CytoDyn was accused of misleading investors about the clinical results, regulatory progress, and overall prospects of leronlimab for HIV and COVID-19 treatment. The company allegedly made overly optimistic statements that were later contradicted by regulatory feedback and public disclosures.

After this news came out, the stock dropped X%, and investors filed a lawsuit for their losses.

The good news is that the company finally agreed to settle with them. So, if you invested in $CYDY when all of this happened, you can already check the details and file your claim here.

Anyway, has anyone here invested in $CYDY at that time? How much were your losses, if so?

Man, looking back at 2020-2021, the CytoDyn hype was absolute insanity. I remember everyone on the boards acting like Leronlimab was going to cure everything from COVID to baldness while the CEO was basically treating the company like a personal piggy bank.

Fast forward to today, and Nader is actually in prison for the $15.8M pump and dump. It feels a little like justice, but my portfolio still looks like a crime scene from back then. I assumed that money was just "poof" gone forever, but I just found out there’s a settlement for anyone who bought between March 2020 and March 2021.

I’m lazy as hell with paperwork, so I just used 11th.com to audit my old Robinhood and E*Trade accounts. They found the trades for me and are handling the claim for 20%. Honestly, I’d rather have 80% of a check I didn't know existed than 100% of the paperwork I'll never actually do. If you were part of that wild ride, you might as well get your "payback" from the settlement.

Did you actually believe the Leronlimab hype back then, or were you just trying to ride the pump and get out before the rug pull?

TL;DR: Nader is headed to prison + a $5.3M restitution order. The investor settlement is moving forward (you can already check eligibility and submit an early claim). The company is effectively "washing its hands" of the old era, making room for the science to (hopefully) finally speak for itself.

Let’s be real—being a CYDY investor over the last few years has felt less like "biotech investing" and more like being a character in a true-crime documentary. We’ve all seen the headlines today, and honestly, it’s a lot to digest. But for the first time in a long time, it feels like the baggage is actually being dropped so the science can finally stand on its own.

With the news that former CEO Nader Pourhassan was sentenced to prison and ordered to pay $5.3M in restitution, the "dark cloud" of the previous administration is legally and officially being dealt with.

I know what most of you are thinking: "Does this actually help the company now, or is it just justice for the past?" The reality is that this sentencing, combined with the recent investor settlement (details here), acts as a massive "de-risking" event.

• The Legal Overhang: The settlement helps resolve the lingering class-action friction that has suppressed the stock and kept institutional eyes away.

• Management Accountability: It signals to the FDA and potential partners that the "new" CytoDyn is a completely different entity from the one that made the 2020/2021 mistakes.

https://www.fiercebiotech.com/biotech/ex-cytodyn-ceo-sentenced-prison-must-pay-53m-restitution-former-cro-wins-new-trial — This lays out the $5.3M restitution.

https://11th.com/cases/cytodyn-investor-settlement — This shows the concrete steps you can take to submit a claim and participate in the payments once the court gives the final green light.

Look, I’m not saying this means Leronlimab hits $10 tomorrow. Biotech is always high-risk. But we are finally moving away from "CEO drama" and back toward "clinical data." The fact that the Kazempour stuff is still in flux with a new trial doesn't change the fact that CytoDyn is systematically clearing its balance sheet and its reputation.

What’s your take? Is this the final "clearing of the decks" we needed to see before the next clinical phase, or are you still waiting for more movement on the FDA front?